[ Cost Hub → Genetic Testing Cost · Insurance ]

Is Genetic Testing Covered by Insurance?

Sometimes — and the rules are knowable. Hereditary cancer testing is covered when you meet NCCN criteria. PGx coverage is growing through medical-necessity documentation. Here is the complete criteria map, the CPT codes, and how we verify your benefits before you spend a dollar.

By Dr. Michael Okonkwo, Chief Medical OfficerMedically reviewed by Shawn Desai, MD, PhD, Lab Director & Medical DirectorAugust 2026

When Insurance Pays — NCCN Criteria

Clinical laboratory where hereditary cancer genetic tests are analyzed

The National Comprehensive Cancer Network (NCCN) publishes the guidelines most insurers follow for hereditary cancer testing. Coverage is likely if any of these apply to you:

  • Personal breast cancer before age 50
  • Personal ovarian cancer at any age
  • A male relative with breast cancer
  • Ashkenazi Jewish ancestry
  • Two or more family members with breast, ovarian, or pancreatic cancer
  • A known BRCA mutation in a first-degree relative

For pharmacogenomic testing, insurers look for documented medical necessity — a planned medication with a known gene-drug interaction (clopidogrel/CYP2C19, codeine/CYP2D6, many antidepressants), or a history of failed medication trials. Medicare covers PGx in defined clinical contexts; commercial coverage is expanding as of 2026.

The CPT Code Table

[ 2026 Fee Schedules ]
CPT CodeTest Billed2026 Typical Billed RangeCoverage Trigger
81432BRCA1/BRCA2 full gene sequence analysis$2,100 – $2,800 (Medicare/commercial fee schedules)NCCN criteria met
81433BRCA1/BRCA2 deletion/duplication analysis$850 – $1,200NCCN criteria met, usually billed with 81432
81435Hereditary colon cancer syndromes panel (e.g., Lynch syndrome)$1,500 – $2,400Family history / NCCN criteria for Lynch screening
81479Unlisted molecular pathology — pharmacogenomic analysis$300 – $1,200Physician-documented medical necessity

These billed ranges are what hospital and clinical labs charge insurers — the reason a pre-verified $0-coverage answer or a $499 cash price both beat an unverified claim. Gene Matrix includes CPT-coded receipts with every order for reimbursement and HSA/FSA documentation.

Our Pre-Verification Process

[ Know Your Cost Before You Commit ]
Step 1

You Ask

Contact us with your insurance card and the test you are considering. No obligation, no charge.

Step 2

We Verify

Our team checks your plan’s criteria against NCCN and medical-necessity guidelines, and secures pre-authorization where required.

Step 3

You Get a Number

We tell you your exact out-of-pocket cost — deductible, coinsurance, or $0 — before you order. If coverage is denied, we quote the cash price instead.

Step 4

You Decide

Proceed through insurance, pay cash (often with HSA/FSA pre-tax dollars), or walk away. You will never receive a surprise bill from us.

Out of network? We generate a superbill — an itemized, CPT-coded receipt formatted for insurance reimbursement — for every order on request. Submit it to your insurer for out-of-network reimbursement. Start pre-verification →

Not Covered? You Still Have Options.

If you don’t meet NCCN criteria, the cash path is built to be painless: $249–$599 per test with every price published, all 11 tests for $89/month (or $59/mo billed annually, $712/yr), HSA/FSA cards accepted for a 22–35% pre-tax discount, and a 30-day money-back guarantee. The same CLIA-certified lab and the same up-to-99.9% analytical accuracy either way.

[ Pre-Verified Before You Pay ][ Superbills Provided ][ HSA / FSA Accepted ]

Insurance Questions, Answered

Most major insurers cover hereditary cancer testing when you meet NCCN criteria — for example breast cancer before age 50, ovarian cancer at any age, a male relative with breast cancer, Ashkenazi Jewish ancestry, two or more family members with breast/ovarian/pancreatic cancer, or a known BRCA mutation in a first-degree relative. Claims bill under CPT 81432 (sequencing), 81433 (deletion/duplication), and 81435 (Lynch syndrome panels). Gene Matrix verifies your benefits before you order.

Coverage is growing but inconsistent as of 2026. Medicare covers PGx testing in certain clinical contexts, and commercial insurers increasingly approve it when a physician documents medical necessity — for example before prescribing a drug with a known gene-drug interaction (clopidogrel/CYP2C19, codeine/CYP2D6) or after failed medication trials. PGx claims typically bill under CPT 81479. Our team can check your specific plan before you order.

A superbill is an itemized receipt formatted for insurance reimbursement: it lists the provider, lab (CLIA ID 14D2276402), CPT billing codes, diagnosis-supporting information, and amount paid. If Gene Matrix is out of your network, you submit the superbill to your insurer for out-of-network reimbursement. We generate one automatically for every order on request.

You have options. Because we pre-verify before testing, a denial means you simply do not proceed through insurance — you can instead pay the published cash price ($249–$599 per test, or all 11 tests with the $89/month membership), often with HSA/FSA pre-tax dollars for a 22–35% effective discount. There is never a surprise bill: you know your cost before your sample is ever processed.

Genetic testing claims are among the most frequently denied in diagnostics when criteria are not documented upfront. Pre-verification confirms your plan’s criteria, secures pre-authorization where required, and tells you your exact out-of-pocket cost — deductible, coinsurance, or $0 — before you commit. It converts a gamble into a known number.

The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information to set premiums, deny coverage, or make eligibility decisions. GINA does not extend to life, disability, or long-term-care insurance — something to consider before testing. Your genetic counselor can walk you through the nuances before you decide.

Chief Medical Officer · Gene Matrix
Medically reviewed by Shawn Desai, MD, PhD, Lab Director & Medical Director · August 2026